{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:26:27Z","timestamp":1767677187220},"reference-count":40,"publisher":"FapUNIFESP (SciELO)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Neuro-Psiquiatr."],"abstract":"<jats:p>Natalizumab is currently one of the best options for treatment of patients with Multiple Sclerosis who have failed traditional prior therapies. However, prolonged use, prior immunosuppressive therapy and anti-JCV antibody status have been associated with increased risk of developing progressive multifocal leukoencephalopathy (PML). The evaluation of these conditions has been used to estimate risks of PML in these patients, and distinct (sometimes extreme) approaches are used to avoid the PML onset. At this time, the biggest issue facing the use of Natalizumab is how to get a balance between the risks and the benefits of the treatment. Hence, strategies for monitor JCV-positive patients undergoing Natalizumab treatment are deeply necessary. To illustrate it, we monitored JCV\/DNA in blood and urine of a patient receiving Natalizumab for 12 months. We also bring to discussion the effectiveness of the current methods used for risk evaluation, and the real implications of viral reactivation.<\/jats:p>","DOI":"10.1590\/0004-282x20140142","type":"journal-article","created":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T18:33:36Z","timestamp":1417286016000},"page":"960-965","source":"Crossref","is-referenced-by-count":10,"title":["Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients"],"prefix":"10.1590","volume":"72","author":[{"given":"Luiz Henrique da Silva","family":"Nali","sequence":"first","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenira","family":"Moraes","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina Domingues","family":"Fink","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagoberto","family":"Callegaro","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila Malta","family":"Romano","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusto Cesar Penalva de","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Instituto de Infectologia Emilio Ribas, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2014,12,2]]},"reference":[{"issue":"6364","key":"ref1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock TA","year":"1992","journal-title":"Nature"},{"issue":"9","key":"ref2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman CH","year":"2006","journal-title":"N Engl J Med"},{"key":"ref3","first-page":"399","article-title":"Progressive multifocal encephalopathy","volume":"123","author":"Greenlee JE","year":"1998","journal-title":"Handb Clin Neurol"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1590\/S0036-46652008000400004","article-title":"Aids-related progressive multifocal leukoencephalopathy: a retrospective study in a referral center in Sao Paulo, Brazil","volume":"50","author":"Vidal JE","year":"2008","journal-title":"Rev Inst Med Trop S\u00e3o Paulo"},{"key":"ref5","series-title":"Field's virology","first-page":"2263","volume-title":"Polyomaviruses","author":"Imperiale MJ","year":"2007"},{"issue":"20","key":"ref6","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1002\/pmic.200600261","article-title":"Viral proteomics: a promising approach for understanding JC virus tropism","volume":"6","author":"Ravichandran V","year":"2006","journal-title":"Proteomics"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S1386-6532(03)00155-0","article-title":"Detection of BK virus and JC virus DNA in urine samples from immunocompromised (HIV-infected) and immunocompetent (HIV-non-infected) patients using polymerase chain reaction and microplate hybridisation","volume":"29","author":"Behzad-Behbahani A","year":"2004","journal-title":"J Clin Virol"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/jmv.20829","article-title":"Presence, quantitation and characterization of JC virus in the urine of Italian immunocompetent subjects","volume":"79","author":"Rossi A","year":"2007","journal-title":"J Med Virol"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1590\/S0036-46652012000400004","article-title":"High prevalence of the simultaneous excretion of polyomaviruses JC and BK in the urine of HIV-infected patients without neurological symptoms in Sao Paulo, Brazil","volume":"54","author":"Nali LHS","year":"2012","journal-title":"Rev Inst Med Trop S\u00e3o Paulo"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1128\/JVI.64.6.3139-3143.1990","article-title":"Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals","volume":"64","author":"Yogo Y","year":"1990","journal-title":"J Virol"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"5672","DOI":"10.1128\/JVI.75.12.5672-5676.2001","article-title":"JC virus regulatory region tandem repeats in plasma and central nervous system isolates correlate with poor clinical outcome in patients with progressive multifocal leukoencephalopathy","volume":"75","author":"Pfister LA","year":"2001","journal-title":"J Virol"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/jnnp.71.3.397","article-title":"JC virus regulatory region rearrangements in the brain of a long surviving patient with progressive multifocal leukoencephalopathy","volume":"71","author":"Yogo Y","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","article-title":"Asymptomatic reactivation of JC virus in patients treated with natalizumab","volume":"361","author":"Chen Y","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s11481-010-9203-1","article-title":"Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy","volume":"5","author":"Marshall LJ","year":"2010","journal-title":"J Neuroimmune Pharmacol"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir256","article-title":"Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients","volume":"204","author":"Reid CE","year":"2011","journal-title":"J Infect Dis"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1128\/JVI.66.10.5726-5734.1992","article-title":"JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy","volume":"66","author":"White FA","year":"1992","journal-title":"J Virol"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0042-6822(92)90167-N","article-title":"Evidence of human polyomavirus BK and JC infection in normal brain tissue","volume":"191","author":"Elsner C","year":"1992","journal-title":"Virology"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"9918","DOI":"10.1128\/JVI.72.12.9918-9923.1998","article-title":"Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection","volume":"72","author":"Monaco MC","year":"1998","journal-title":"J Virol"},{"issue":"18","key":"ref19","doi-asserted-by":"crossref","first-page":"9200","DOI":"10.1128\/JVI.00609-10","article-title":"JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy","volume":"84","author":"Tan CS","year":"2010","journal-title":"J Virol"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","article-title":"Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab","volume":"18","author":"Sorensen PS","year":"2012","journal-title":"Mult Scler"},{"issue":"7","key":"ref21","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1099\/vir.0.020115-0","article-title":"Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians","volume":"91","author":"Antonsson A","year":"2010","journal-title":"J Gen Virol"},{"issue":"6","key":"ref22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/597126","article-title":"Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors","volume":"199","author":"Egli A","year":"2009","journal-title":"J Infect Dis"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.22606","article-title":"Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1","volume":"70","author":"Bozic C","year":"2011","journal-title":"Ann Neurol"},{"issue":"3","key":"ref24","article-title":"Seroepidemiology of human polyomaviruses","volume":"5","author":"Kean JM","year":"2009","journal-title":"PLoS Pathog"},{"issue":"22","key":"ref25","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0b013e3182583022","article-title":"Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort","volume":"78","author":"Trampe AK","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1756285612470401","article-title":"Best practice in the use of natalizumab in multiple sclerosis","volume":"6","author":"Fernandez O","year":"2013","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/ana.22074","article-title":"Natalizumab drug holiday in multiple sclerosis: poorly tolerated","volume":"68","author":"Killestein J","year":"2010","journal-title":"Ann Neurol"},{"issue":"18","key":"ref28","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/WNL.0b013e318253d61e","article-title":"Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS","volume":"78","author":"Gheuens S","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jviromet.2006.01.018","article-title":"Real-time, quantitative PCR assays for the detection of virus-specific DNA in samples with mixed populations of polyomaviruses","volume":"135","author":"Pal A","year":"2006","journal-title":"J Virol Methods"},{"issue":"3","key":"ref30","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s11481-012-9366-z","article-title":"Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification","volume":"7","author":"Laroni A","year":"2012","journal-title":"J Neuroimmune Pharmacol"},{"issue":"20","key":"ref31","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1128\/JVI.00614-10","article-title":"Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate","volume":"84","author":"Gosert R","year":"2010","journal-title":"J Virol"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/viro.1995.0001","article-title":"Transcriptional regulation: lessons from the human neurotropic polyomavirus, JCV","volume":"213","author":"Raj GV","year":"1995","journal-title":"Virology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"10489","DOI":"10.1128\/JVI.73.12.10489-10502.1999","article-title":"Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection","volume":"73","author":"Shankarappa R","year":"1999","journal-title":"J Virol"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrg1246","article-title":"The causes and consequences of HIV evolution","volume":"5","author":"Rambaut A","year":"2004","journal-title":"Nat Rev Genet"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.hepres.2004.02.014","article-title":"Changes of HCV quasispecies during combination therapy with interferon and ribavirin","volume":"29","author":"Ueda E","year":"2004","journal-title":"Hepatol Res"},{"issue":"5","key":"ref36","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1099\/0022-1317-81-5-1191","article-title":"Evolution of human polyomavirus JC","volume":"81","author":"Hatwell JN","year":"2000","journal-title":"J Gen Virol"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1615\/CritRevImmunol.v28.i2.40","article-title":"Immune responses against persistent viral infections: possible avenues for immunotherapeutic interventions","volume":"28","author":"Fuse S","year":"2008","journal-title":"Crit Rev Immunol"},{"issue":"12","key":"ref38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052208","article-title":"Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis","volume":"7","author":"Benkert TF","year":"2012","journal-title":"PLoS ONE"},{"issue":"11","key":"ref39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047578","article-title":"Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis","volume":"7","author":"Bornsen L","year":"2012","journal-title":"PLoS ONE"},{"issue":"11","key":"ref40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003014","article-title":"Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"8","author":"Perkins MR","year":"2012","journal-title":"PLoS Pathog"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/anp\/v72n12\/0004-282X-anp-282X20140142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T09:45:59Z","timestamp":1598521559000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-282X2014001200960&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,2]]},"references-count":40,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12]]}},"alternative-id":["S0004-282X2014001200960"],"URL":"https:\/\/doi.org\/10.1590\/0004-282x20140142","relation":{},"ISSN":["1678-4227","0004-282X"],"issn-type":[{"value":"1678-4227","type":"electronic"},{"value":"0004-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12,2]]}}}